^
Association details:
| Biomarker: | FLT3 Y842C |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + crenolanib (ARO-002) (FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Excerpt:
...combining the type I TK inhibitor crenolanib with the type II TK inhibitor sorafenib in sorafenib-resistant cells. This combination showed profound synergistic pro-apoptotic effects even at 10-fold lower concentrations than the growth inhibitory concentrations of crenolanib as single agent treatment.
DOI:
https://dx.doi.org/10.1158%2F1078-0432.CCR-13-2052
